{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T11:10:04Z","timestamp":1791112204355,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1016\/j.neuropharm.2004.11.009","type":"journal-article","created":{"date-parts":[[2005,2,2]],"date-time":"2005-02-02T08:46:55Z","timestamp":1107334015000},"page":"517-524","source":"Crossref","is-referenced-by-count":80,"title":["KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse"],"prefix":"10.1016","volume":"48","author":[{"given":"Mette","family":"Pierri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Vaudano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Sager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrica","family":"Englund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2004.11.009_bib1","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1111\/j.1471-4159.1987.tb05752.x","article-title":"Biochemical and pharmacological characterization of [3H]GBR 12935 binding in vitro to rat striatal membranes: labeling of the dopamine uptake complex","volume":"48","author":"Andersen","year":"1987","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2004.11.009_bib2","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/0014-2999(89)90363-4","article-title":"The dopamine inhibitor GBR 12909: selectivity and molecular mechanism of action","volume":"166","author":"Andersen","year":"1989","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2004.11.009_bib3","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1212\/01.WNL.0000095213.86899.21","article-title":"Caffeinated clues from epidemiology of Parkinson's disease","volume":"61","author":"Ascherio","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2004.11.009_bib4","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/81834","article-title":"Chronic systemic pesticide exposure reproduces features of parkinson's disease","volume":"3","author":"Betarbet","year":"2000","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2004.11.009_bib5","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/glia.10243","article-title":"Blockade of A2A adenosine receptors prevents basic fibroblast growth factor-induced reactive astrogliosis in rat striatal primary astrocytes","volume":"43","author":"Brambilla","year":"2003","journal-title":"Glia"},{"key":"10.1016\/j.neuropharm.2004.11.009_bib6","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1212\/01.WNL.0000095215.97585.59","article-title":"Monoamine oxidase B inhibition and neuroprotection: studies on selective adenosine A2A receptor antagonists","volume":"61","author":"Castagnoli","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2004.11.009_bib7","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1212\/01.WNL.0000095223.08711.48","article-title":"Translating A2A antagonist KW6002 from animal models to parkinsonian patients","volume":"61","author":"Chase","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2004.11.009_bib8","doi-asserted-by":"crossref","first-page":"RC143","DOI":"10.1523\/JNEUROSCI.21-10-j0001.2001","article-title":"Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease","volume":"21","author":"Chen","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2004.11.009_bib9","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1046\/j.1471-4159.2001.00389.x","article-title":"Functional striatal hypodopaminergic activity in mice lacking adenosine A(2A) receptors","volume":"78","author":"Dassesse","year":"2001","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2004.11.009_bib10","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1097\/00001756-200310270-00009","article-title":"COX-2-deficient mice are less prone to MPTP-neurotoxicity than wild-type mice","volume":"14","author":"Feng","year":"2003","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2004.11.009_bib11","doi-asserted-by":"crossref","first-page":"7238","DOI":"10.1073\/pnas.88.16.7238","article-title":"Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes","volume":"88","author":"Ferre","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.neuropharm.2004.11.009_bib12","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/(SICI)1098-1136(199610)18:2<152::AID-GLIA7>3.0.CO;2-2","article-title":"Cyclooxygenase-2 expression in rat microglia is induced by adenosine A2a-receptors","volume":"18","author":"Fiebich","year":"1996","journal-title":"Glia"},{"key":"10.1016\/j.neuropharm.2004.11.009_bib13","first-page":"143","article-title":"Nomenclature and classification of purinoceptors","volume":"46","author":"Fredholm","year":"1994","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2004.11.009_bib14","first-page":"83","article-title":"Actions of caffeine in the brain with special reference to factors that contribute to its widespread use","volume":"51","author":"Fredholm","year":"1999","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2004.11.009_bib15","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1212\/01.WNL.0000095206.44418.5C","article-title":"Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson's disease","volume":"61","author":"Fuxe","year":"2003","journal-title":"Neurology"},{"issue":"Pt 1","key":"10.1016\/j.neuropharm.2004.11.009_bib16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2818.1986.tb02764.x","article-title":"Stereology of arbitrary particles. A review of unbiased number and size estimators and the presentation of some new ones, in memory of William R Thompson","volume":"143","author":"Gundersen","year":"1986","journal-title":"J. Microsc."},{"key":"10.1016\/j.neuropharm.2004.11.009_bib17","first-page":"925","article-title":"Dopamine (3-hydroxytyramine) and brain function","volume":"18","author":"Hornykiewicz","year":"1966","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2004.11.009_bib18","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1002\/ana.10481","article-title":"Neuroinflammatory processes in Parkinson's disease","volume":"53","author":"Hunot","year":"2003","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2004.11.009_bib19","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1046\/j.0022-3042.2001.00694.x","article-title":"Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease","volume":"80","author":"Ikeda","year":"2002","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2004.11.009_bib20","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1212\/01.WNL.0000095209.59347.79","article-title":"A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD","volume":"61","author":"Jenner","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2004.11.009_bib21","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1471-4159.1993.tb03215.x","article-title":"Protection against acute MPTP-induced dopamine depletion in mice by adenosine A1 agonist","volume":"60","author":"Lau","year":"1993","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2004.11.009_bib22","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1523\/JNEUROSCI.19-04-01284.1999","article-title":"Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurones","volume":"19","author":"Lotharius","year":"1999","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2004.11.009_bib23","doi-asserted-by":"crossref","first-page":"38581","DOI":"10.1074\/jbc.M005385200","article-title":"The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism for toxicity","volume":"275","author":"Lotharius","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2004.11.009_bib24","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1212\/01.WNL.0000095211.71092.A0","article-title":"Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonists","volume":"61","author":"Mori","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2004.11.009_bib25","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1254\/jjp.60.311","article-title":"In vivo release of dopamine by perfusion of 1-methyl-4-phenylpyridinium ion in the striatum with a microdialysis technique","volume":"60","author":"Obata","year":"1992","journal-title":"Jpn. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2004.11.009_bib26","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s00702-001-0683-2","article-title":"Dopamine efflux by MPTP and hydroxyl radical generation","volume":"109","author":"Obata","year":"2002","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.neuropharm.2004.11.009_bib27","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0301-0082(02)00127-2","article-title":"An inflammatory review of Parkinson's disease","volume":"68","author":"Orr","year":"2002","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2004.11.009_bib28","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S0968-0896(02)00648-X","article-title":"Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists","volume":"11","author":"Petzer","year":"2003","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.neuropharm.2004.11.009_bib29","doi-asserted-by":"crossref","first-page":"S175","DOI":"10.1002\/ana.410440726","article-title":"Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection","volume":"44","author":"Rodriguez","year":"1998","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2004.11.009_bib30","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/(SICI)1096-9861(19981116)401:2<163::AID-CNE2>3.0.CO;2-D","article-title":"Immunohistochemical localization of adenosine A2A receptors in the rat central nervous system","volume":"401","author":"Rosin","year":"1998","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.neuropharm.2004.11.009_bib31","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1212\/01.WNL.0000095205.33940.99","article-title":"Anatomy of adenosine A2A receptors in brain: morphological substrates for integration of striatal function","volume":"61","author":"Rosin","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2004.11.009_bib32","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1212\/01.WNL.0000095207.66853.0D","article-title":"A2A receptor and striatal cellular functions: regulation of gene expression, currents, and synaptic transmission","volume":"61","author":"Schiffmann","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2004.11.009_bib33","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1212\/WNL.58.8.1154","article-title":"Caffeinated clues and the promise of adenosine A(2A) antagonists in PD","volume":"58","author":"Schwarzschild","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2004.11.009_bib34","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1212\/01.WNL.0000095214.53646.72","article-title":"Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease","volume":"61","author":"Schwarzschild","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2004.11.009_bib35","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0301-0082(95)00035-6","article-title":"Adenosine A2 receptor-mediated excitatory actions on the nervous system","volume":"48","author":"Sebastiao","year":"1996","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2004.11.009_bib36","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1212\/01.WNL.0000095581.20961.7D","article-title":"Discovery of nonxanthine adenosine A2A receptor antagonists for the treatment of Parkinson's disease","volume":"61","author":"Weiss","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2004.11.009_bib37","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0166-2236(98)01362-9","article-title":"Stereological methods for estimating the total number of neurones and synapses: issues of precision and bias","volume":"22","author":"West","year":"1999","journal-title":"Trends. Neurosci."},{"key":"10.1016\/j.neuropharm.2004.11.009_bib38","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1212\/WNL.47.3.718","article-title":"Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease","volume":"47","author":"Wilson","year":"1996","journal-title":"Neurology"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390804003880?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390804003880?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T19:28:03Z","timestamp":1548790083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390804003880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["S0028390804003880"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2004.11.009","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2005,3]]}}}